Cambridge, Massachusetts-based Vedanta Biosciences, a late clinical-stage company developing microbiome-based oral therapies for gastrointestinal disease, has secured USD 60 million in funding ahead of pivotal Phase III data for its lead candidate, VE303 (a defined bacterial consortium live biotherapeutic product), in recurrent Clostridioides difficile infection (CDI).
The raise comprises a USD 40 million equity financing round led by existing investors AMR Action Fund and BNP Paribas Asset Management Alts, disbursed in two tranches of approximately USD 18 million in Q1 and USD 22 million in Q2, alongside an additional USD 20 million awarded under Vedanta's existing contract with the Biomedical Advanced Research and Development Authority (BARDA). Proceeds are designated to support the ongoing Phase III RESTORATiVE303 registrational study through topline efficacy data expected in the first half of 2027. The financing follows a USD 106.5 million Series E closed in April 2023, co-led by AXA IM Alts and AMR Action Fund, bringing total capital raised by the company to well in excess of USD 350 million including prior equity rounds, BARDA contract funding, and grants from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
VE303 consists of eight rationally selected bacterial strains designed to restore colonisation resistance against C. difficile following antibiotic treatment, manufactured from pure clonal cell banks rather than donor fecal material. The RESTORATiVE303 trial, enrolling patients across more than 150 sites in approximately 20 countries, has crossed 80% enrollment and is on track to complete enrollment in the second half of 2026. An independent Data Monitoring Committee completed a prespecified interim analysis earlier this year and recommended the study continue without modification, the company said, having determined that efficacy exceeded the prespecified futility threshold with no new safety signals. VE303 holds Orphan Drug and Fast Track designations from the US FDA; positive topline data would support a Biologics License Application (BLA) submission. The company's second programme, VE202, a defined bacterial consortium evaluated in ulcerative colitis, did not meet its primary endpoint in a completed Phase II study.
If successful, VE303 would enter a recurrent CDI market that already includes US FDA-approved microbiota-based therapies Rebyota (Ferring Pharmaceuticals) and Vowst (Seres Therapeutics), while differentiating itself through a defined bacterial composition produced without donor-derived fecal material.